Ergoteles’s Keros Therapeutics KROS Stock Holding History

Ergoteles’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,049	Closed	-$685K	–	1276
2023 Q1	$685K	Buy	+16,049	New	+$811K	0.03%	630

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ergoteles's KROS Position: Q2 2023 in Review

Ergoteles sold out of Keros Therapeutics (KROS) in Q2 2023, closing a stake of 16,049 shares — an estimated $685K sold.

Ergoteles first reported a position in KROS in Q1 2023 and held it in 1 quarter. The position peaked at $685K in Q1 2023. 123 funds tracked by Wall St. Rank hold KROS as of Q2 2023.

Ergoteles reported no remaining Keros Therapeutics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 16,049 Keros Therapeutics shares in Q2 2023, an estimated $685K.
Ergoteles first reported a position in Keros Therapeutics in Q1 2023 and held it in 1 quarter.
Ergoteles's Keros Therapeutics position peaked at $685K in Q1 2023.
123 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.